The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

NCT06117137 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Fatty Liver, Nonalcoholic

Interventions

DRUG: SGLT2 inhibitor

Sponsor

Sohag University